• Overview
  • Eligibility
  • More info
  • Locations

Phase II Evaluation of Dolastatin-10 in Patients With Hormone Refractory Prostate Cancer (NCT00003626)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with metastatic prostate cancer that has not responded to previous hormone therapy.
  • Drug: dolastatin 10
    Ages eligible for Study
    all
    Genders eligible for Study
    Male
    Accepts Healthy Volunteers
    No
    OBJECTIVES: I. Determine the objective response rate in patients with hormone refractory prostate cancer treated with dolastatin 10. II. Determine the toxicity of this regimen in this patient population.

    OUTLINE: Patients receive dolastatin 10 IV bolus every 3 weeks. Treatment continues for a minimum of 2 courses in the absence of unacceptable toxicity or disease progression.

    PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study.

    3 locations

    United States (3)
    • University of Colorado Cancer Center
      Denver, Colorado, United States, 80262
    • Barbara Ann Karmanos Cancer Institute
      Detroit, Michigan, United States, 48201
    • Fox Chase Cancer Center
      Philadelphia, Pennsylvania, United States, 19111
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 September, 1998
    Updated:
    02 April, 2013
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!